Fig. 2: TP53 immunohistochemistry and TP53 mutations by sequencing in ovarian mucinous tumors. | Modern Pathology

Fig. 2: TP53 immunohistochemistry and TP53 mutations by sequencing in ovarian mucinous tumors.

From: Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

Fig. 2: TP53 immunohistochemistry and TP53 mutations by sequencing in ovarian mucinous tumors.

Ovarian mucinous tumors with variable percentages of TP53 overexpression: a 5% overexpression or >12 consecutive strongly staining cells. b 50% overexpression. c 70% overexpression. d 100% overexpression. e concordance between mutation status by sequencing and immunohistochemistry improved with application of refined (minimum 5% abnormal OE pattern) instead of established criteria, with improvements observed in cases with splicing and missense mutations. f The percentage of tumor cells overexpressing TP53 in mucinous borderline tumors (MBOT) and carcinomas (MOC) (median 35% and N = 11 in MBOT; median 60% and N = 69 in MOC; p = 0.040). g TP53 mutation allele frequencies in MBOT and MOC (median 0.44 and 0.55, respectively; p = 0.38).

Back to article page